Mirae Asset Global Investments
CARM

Mirae Asset Global Investments’s Carisma Therapeutics CARM Stock Holding History

Mirae Asset Global Investments’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,244
Closed -$60.3K – 2537
2023
Q3 		$60.3K Hold
14,244
– – ﹤0.01% 2537
2023
Q2 		$125K Buy
+14,244
New +$77.5K ﹤0.01% 2456

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mirae Asset Global Investments's CARM Position: Q4 2023 in Review

Mirae Asset Global Investments sold out of Carisma Therapeutics (CARM) in Q4 2023, closing a stake of 14,244 shares — an estimated $60.3K sold.

Mirae Asset Global Investments first reported a position in CARM in Q2 2023 and held it in 2 quarters. The position peaked at $125K in Q2 2023. 50 funds tracked by Wall St. Rank hold CARM as of Q4 2023.

  • Mirae Asset Global Investments reported no remaining Carisma Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Mirae Asset Global Investments sold 14,244 Carisma Therapeutics shares in Q4 2023, an estimated $60.3K.
  • Mirae Asset Global Investments first reported a position in Carisma Therapeutics in Q2 2023 and held it in 2 quarters.
  • Mirae Asset Global Investments's Carisma Therapeutics position peaked at $125K in Q2 2023.
  • 50 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2023.

Based on Mirae Asset Global Investments's 13F filing for Q4 2023, filed 24 Jan 2024.